# Study to Assess the Bioequivalence Between Ticagrelor Orodispersible Tablets and Ticagrelor Immediate-release Tablets in Japanese Subjects

> **NCT02436577** · PHASE1 · COMPLETED · sponsor: **AstraZeneca** · enrollment: 51 (actual)

## Conditions studied

- Bioequivalence
- Healthy Japanese Subjects
- Pharmacokinetics

## Interventions

- **DRUG:** Ticagrelor OD tablet (90 mg single dose) administered with 150 mL of water
- **DRUG:** Ticagrelor OD tablet (90 mg single dose) administered without water
- **DRUG:** Ticagrelor IR tablet (90 mg) administered with 150 mL of water

## Key facts

- **NCT ID:** NCT02436577
- **Lead sponsor:** AstraZeneca
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-06
- **Primary completion:** 2015-08
- **Final completion:** 2015-08
- **Target enrollment:** 51 (ACTUAL)
- **Last updated:** 2017-01-11


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02436577

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02436577, "Study to Assess the Bioequivalence Between Ticagrelor Orodispersible Tablets and Ticagrelor Immediate-release Tablets in Japanese Subjects". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT02436577. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*